Equity Details
Price & Market Data
Price: $7.23
Daily Change: +$0.425 / 5.88%
Daily Range: $6.80 - $7.23
Market Cap: $29,247,608
Daily Volume: 12,545
Performance Metrics
1 Week: 1.76%
1 Month: 2.05%
3 Months: -7.13%
6 Months: -34.50%
1 Year: -5.37%
YTD: -17.71%
About Kyntra Bio, Inc. (KYNB)
Essential market details for Kyntra Bio, Inc. (KYNB). Current price: 7.23, daily change: +$0.425 / 5.88%. Market cap: 29,247,608. Dive into YTD, 1-week, and 6-month performance.
Company Details
Employees: 34
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.